Chaudhri Kanika, Kearney Madeleine, Day Richard O, Rodgers Anthony, Atkins Emily
Cardiovascular Division, The George Institute for Global Health, Sydney, New South Wales, Australia
Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
BMJ Open. 2019 Oct 3;9(10):e030536. doi: 10.1136/bmjopen-2019-030536.
Forgetting to take a medication is the most common reason for non-adherence to self-administered medication. Dose administration aids (DAAs) are a simple and common solution to improve unintentional non-adherence for oral tablets. DAAs can be in the form of compartmentalised pill boxes, automated medication dispensing devices, blister packs and sachets packets. This protocol aims to outline the methods that will be used in a systematic review of the current literature to assess the impact of DAAs on adherence to medications and health outcomes.
Randomised controlled trials will be identified through electronic searches in databases including EMBASE, MEDLINE, CINAHL and the Cochrane Library, from the beginning of each database until January 2020. Two reviewers will independently screen studies and extract data using the standardised forms. Data extracted will include general study information, characteristics of the study, participant characteristics, intervention characteristics and outcomes. Primary outcome is to assess the effects of DAAs on medication adherence. Secondary outcome is to evaluate the changes in health outcomes. The risk of bias will be ascertained by two reviewers in parallel using The Cochrane Risk of Bias Tool. A meta-analysis will be performed if data are homogenous.
Ethics approval will not be required for this study. The results of the review described within this protocol will be disseminated through publication in a peer-reviewed journal and relevant conference presentations.
CRD42018096087.
忘记服药是不坚持自行服药的最常见原因。剂量给药辅助工具（DAAs）是一种简单且常见的解决方法，可改善口服片剂的无意性不依从情况。DAAs可以是分隔式药盒、自动配药装置、泡罩包装和小药包的形式。本方案旨在概述将用于系统评价当前文献的方法，以评估DAAs对药物依从性和健康结局的影响。
通过在包括EMBASE、MEDLINE、CINAHL和Cochrane图书馆在内的数据库中进行电子检索，从每个数据库创建之初至2020年1月，识别随机对照试验。两名评审员将独立筛选研究并使用标准化表格提取数据。提取的数据将包括一般研究信息、研究特征、参与者特征、干预特征和结局。主要结局是评估DAAs对药物依从性的影响。次要结局是评估健康结局的变化。两名评审员将并行使用Cochrane偏倚风险工具确定偏倚风险。如果数据同质，将进行荟萃分析。
本研究无需伦理批准。本方案中所述综述的结果将通过在同行评审期刊上发表及相关会议报告进行传播。
PROSPERO注册号：CRD42018096087。
